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Abstract
Background: Reactive microglia are commonly seen in retinal degenerative diseases, and neurotoxic microglia
responses can contribute to photoreceptor cell death. We and others have previously shown that translocator
protein (18 kDa) (TSPO) is highly induced in retinal degenerations and that the selective TSPO ligand XBD173
(AC-5216, emapunil) exerts strong anti-inflammatory effects on microglia in vitro and ex vivo. Here, we investigated
whether targeting TSPO with XBD173 has immuno-modulatory and neuroprotective functions in two mouse
models of acute retinal degeneration using bright white light exposure.
Methods: BALB/cJ and Cx3cr1GFP/+ mice received intraperitoneal injections of 10 mg/kg XBD173 or vehicle for five
consecutive days, starting 1 day prior to exposure to either 15,000 lux white light for 1 h or 50,000 lux focal light for
10 min, respectively. The effects of XBD173 treatment on microglia and Müller cell reactivity were analyzed by
immuno-stainings of retinal sections and flat mounts, fluorescence-activated cell sorting (FACS) analysis, and mRNA
expression of microglia markers using quantitative real-time PCR (qRT-PCR). Optical coherence tomography (OCT),
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings, and morphometric analyses were
used to quantify the extent of retinal degeneration and photoreceptor apoptosis.
Results: Four days after the mice were challenged with bright white light, a large number of amoeboid-shaped
alerted microglia appeared in the degenerating outer retina, which was nearly completely prevented by treatment
with XBD173. This treatment also down-regulated the expression of TSPO protein in microglia but did not change
the TSPO levels in the retinal pigment epithelium (RPE). RT-PCR analysis showed that the microglia/macrophage
markers Cd68 and activated microglia/macrophage whey acidic protein (Amwap) as well as the pro-inflammatory
genes Ccl2 and Il6 were reduced after XBD173 treatment. Light-induced degeneration of the outer retina was nearly
fully blocked by XBD173 treatment. We further confirmed these findings in an independent mouse model of focal
light damage. Retinas of animals receiving XBD173 therapy displayed significantly more ramified non-reactive
microglia and more viable arrestin-positive cone photoreceptors than vehicle controls.
Conclusions: Targeting TSPO with XBD173 effectively counter-regulates microgliosis and ameliorates light-induced
retinal damage, highlighting a new pharmacological concept for the treatment of retinal degenerations.
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Background
Microglial cells are the resident tissue macrophages of the
central nervous system (CNS), including the retina. In the
healthy retina, they are located in the plexiform layers
from where they permanently scan the retinal environ-
ment with their motile protrusions [1]. Several receptors
that are specific for the binding of chemokines, cytokines,
complement factors, antibodies, or damage-associated
molecular patterns enable these cells to recognize and im-
mediately respond to pathological changes of their envir-
onment [2–4]. Beside their homeostatic function in the
healthy retina, microglia reactivity and age-related changes
of microglia physiology contribute to degenerative path-
ologies of the retina and the entire CNS [3, 5–14]. To-
gether with monocytes and macrophages, microglial cells
are major players in chronic immune processes including
parainflammation [15]. Reactive microglia are detectable
in the damaged photoreceptor layers of patients with de-
generative retinal diseases such as retinitis pigmentosa
and age-related macular degeneration (AMD) [6]. Micro-
glia not only phagocytose dead cells but also take up living
rods in a mouse model for retinitis pigmentosa [10].
Therefore, microglial activation cannot be just regarded as
a bystander effect but rather actively contributes to photo-
receptor cell death during retinal degeneration.
In attempts to better characterize retinal microglia re-
activity and find novel markers, we and others have pre-
viously identified very high expression of translocator
protein (18 kDa) in reactive retinal microglia [16, 17].
Translocator protein (TSPO), previously known as the
peripheral benzodiazepine receptor, likely mediates the
transport of cholesterol into the inner mitochondrial
membrane, where it serves as a precursor for steroids
and neurosteroids [18]. The protein is constitutively
expressed in steroidogenic tissues and up-regulated in ac-
tivated glial cells [19–21]. Glial up-regulation of TSPO is a
major hallmark of neurodegenerative diseases [22], and
various TSPO ligands have been developed as molecular
markers to detect gliosis by means of PET imaging [23].
Specific TSPO ligands are also under investigation as
treatment options for neurological disorders including
Alzheimer’s disease [24], multiple sclerosis [25], neuro-
pathic pain [26], peripheral nerve injury [22], and anx-
iety disorders [27]. Classical synthetic TSPO ligands
such as the benzodiazepine derivative 4′-chlorodiazepam
(Ro5-4864) and the isoquinoline carboxamide PK11195
directly enhance GABAergic neurotransmission [28]. In
contrast, structurally different synthetic TSPO ligands
such as etifoxine (Stresam) and XBD173 (AC-5216, ema-
punil) also stimulate the synthesis of neurosteroids and
exert potent anti-inflammatory and neuroprotective ef-
fects [29]. XBD173 is a very selective and high-affinity
phenylpurine ligand for TSPO whereas the benzoxazine
etifoxine additionally binds GABAA receptors [30]. Since
XBD173 has a high and specific affinity for TSPO with a
more beneficial side-effect profile than benzodiazepine
derivatives, a precise and potentially long-term applica-
tion to limit neuroinflammation seems feasible.
In a previous report, we have comprehensively charac-
terized the anti-inflammatory effects of the TSPO ligand
XBD173 using murine and human microglial cells as
well as cultured mouse retinal explants [16]. XBD173
strongly suppressed pro-inflammatory gene expression
in LPS-challenged microglia and diminished their neuro-
toxic potential on photoreceptor cell cultures, indicating
that targeting TSPO with XBD173 is a promising ap-
proach to control microglial reactivity [16]. In this study,
we addressed the questions whether XBD173 influences
microglial reactivity in vitro and protects from acute
white light-induced retinal degeneration in two different
mouse models. We selected white light exposure as it is
an environmental risk factor and mimics several features
of human retinal degenerative diseases in rodents [31–33].
This model is also very useful for a quantitative correl-
ation of microglial responses with processes of retinal
degeneration [34–36].
Methods
Reagents
XBD173 (emapunil) was obtained by custom synthesis
from APAC Pharmaceuticals, Ellicott City, MD21042.
XBD173 was dissolved in DMSO.
RNA isolation and reverse transcription
Total RNA was extracted from murine retinas using the
NucleoSpin® RNA Mini Kit (Macherey-Nagel, Dueren,
Germany). RNA was quantified spectrophotometrically
with a NanoDrop 2000 (Thermo Scientific). First-strand
cDNA synthesis was carried out with the Revert Aid H
Minus First-strand cDNA Synthesis Kit (Fermentas,
K1632).
Quantitative RT-PCR
cDNA (25 ng) were amplified in 10 μl reaction mixture
consisting of 5 μl Fast Start Universal Probe Master (Rox)
(Roche), 2 μl of primers (10 μM), 0.375 μl purified water,
and 0.125 μl of dual-labeled UPL probe (Roche Applied
Science, Basel, Switzerland) with an Applied Biosystems
7900 HT Fast Real-Time PCR system (Applied Biosystems,
Carlsbad, CA, USA). The following reaction parameters
were used: 10 min 95 °C hold, followed by 40 cycles of 15 s
95 °C melt, and 1 min 60 °C anneal/extension. Primer se-
quences and UPL probe numbers were as follows: Cd68,
forward primer 5′-ctctctaaggctacaggctgct-3′, reverse primer
5′-tcacggttgcaagagaaaca-3′, probe #27; Amwap, forward
primer 5′-tttgatcactgtggggatga-3′, reverse primer 5′-acacttt
ctggtgaaggcttg-3′, probe #1; Tspo, forward primer 5′-actgta
ttcagccatggggta-3′, reverse primer 5′-accatagcgtcctctgtgaa
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a-3′, probe #33; Il6, forward primer 5′-gatggatgctaccaaactg-
gat-3′, reverse primer 5′-ccaggtagctatggtactccaga-3′, probe
#6; iNos, forward primer 5′-ctttgccacggacgagac-3′, reverse
primer 5′-tcattgtactctgagggctga-3′, probe #13; Ccl2, for-
ward primer 5′-catccacgtgttggctca-3′, reverse primer 5′-gat
catcttgctggtgaatgagt-3′, probe #62; Casp8, forward primer
5′-tgaacaatgagatccccaaat-3′, reverse primer 5′-caaaaatttca
agcaggctca-3′, probe #11; and Atp5b, forward primer 5′-gg
cacaatgcaggaaagg-3′, reverse primer 5′-tcagcaggcacatagata
gcc-3′, probe #77. Measurements were performed in tripli-
cates. Atp5b expression was used as reference gene, and re-
sults were analyzed with the ABI sequence detector
software version 2.4 using the ΔΔCt method for relative
quantification.
Animals
Experiments were performed with 10–14-week-old albino
BALB/cJ mice and Cx3cr1GFP/+ mice on C57BL/6J back-
ground of both sexes. Animals were housed in an air-
conditioned environment with 12-h light-dark schedule
and had free access to water and food. All experimental
procedures complied with the German law on animal pro-
tection and the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. The animal protocols
used in this study were reviewed and approved by the gov-
ernmental body responsible for animal welfare in the state
of Nordrhein-Westfalen (Landesamt für Natur, Umwelt
und Verbraucherschutz Nordrhein-Westfalen, Germany)
(reference number 84-02.04.2015-A039) and by the Ani-
mal Welfare and Ethical Review Board of Queen’s Univer-
sity Belfast under the regulation of the UK Home Office
Animal (Scientific Procedures) Act 1986.
XBD173 administration
The mice received intraperitoneal injections of XBD173
at a dose of 10 mg/kg body weight, dissolved in DMSO
or DMSO vehicle control twice daily for the first 2 days,
starting 1 day before the light exposure and once daily
for the remaining 3 days.
Light exposure regimens
BALB/cJ and Cx3cr1GFP/+ mice were dark-adapted for 16 h
before light exposure. After pupil dilatation with 1 %
phenylephrine and 2.5 % tropicamide under dim red light,
the mice were exposed to bright white light with an inten-
sity of 15,000 lux for 1 h or focal white light with an inten-
sity of 50,000 lux delivered by an otoscope (1218AA, Karl
Storz, Tuttlingen, Germany) for 10 min, respectively. After
light exposure, the animals were housed in dark-reared
conditions overnight and then maintained under normal
light conditions for the remaining experimental period.
Immunohistochemistry
Eyes were harvested for immunohistochemical analysis
4 days after light exposure. After fixation with 4 % parafor-
maldehyde, eyes were embedded in optimal cutting
temperature compound or dissected for retinal flat mount
analysis. Sixteen-micrometer sections were rehydrated with
phosphate-buffered saline (PBS) and blocked with 1 % dried
milk solution containing 0.01 % Triton X-100. Flat mounts
were incubated with 5 % Tween and 5 % Triton X-100 in
PBS overnight, and non-specific binding was blocked by in-
cubation with dried milk solution. Subsequently, retinal
sections and flat mounts were incubated with primary anti-
bodies at 4 °C overnight. Primary antibodies targeting the
following proteins were used: rabbit anti-Iba1 antibody
(dilution 1:500; Wako Chemicals, Neuss, Germany), rabbit
anti-TSPO antibody (dilution 1:250; Abcam, Cambridge,
UK), rabbit anti-glial fibrillary acidic protein (dilution 1:200;
G9269, Sigma, USA), mouse anti-glutamine synthetase
(dilution 1:200; MAB302, Millipore, Darmstadt, Germany),
and rabbit anti-cone arrestin (Millipore, Darmstadt,
Germany). After a washing step, the sections and flat
mounts were incubated with a secondary antibody either
conjugated to Alexa488 (green; dilution 1:1000) or
Alexa594 (red; dilution 1:800) (Jackson Immuno-Research,
West Grove, PA, USA) for 1 h. After counterstaining with
4′,6-Diamidin-2-phenylindol (DAPI) in some instances,
the samples were mounted in DAKO fluorescent mount-
ing medium (Dako Deutschland GmbH, Hamburg,
Germany) and analyzed with an Axioskop2 MOT Plus
Apotome microscope (Carl Zeiss) or an Eclipse TE200-U
confocal microscope (Nikon).
Optical coherence tomography
Animals were anesthetized by intraperitoneal injection of
Rompun (10 mg/kg body weight)-Ketavet (100 mg/kg
body weight), and their pupils were dilated with phenyl-
ephrine HCl (0.25 %)-tropicamide (0.05 %) before image
acquisition. Spectral domain optical coherence tomog-
raphy (SD-OCT) was performed on both eyes with a Spec-
tralis™ HRA+OCT device (Heidelberg Engineering) to
investigate structural changes in the retina after light
exposure and XBD173 administration. Thickness measure-
ments were performed using the Heidelberg Eye Explorer
Software using a circular ring scan (circle diameters 3 and
6 mm), centered on the optic nerve head, which represents
the average retinal thickness (μm) in a certain field.
TUNEL assay and morphometric analyses
Retinal sections were labeled with an in situ cell death
detection kit, fluorescein (Roche), to detect the amount
of apoptotic cells 4 days after light exposure. For a better
overview, the sections were also counterstained with
DAPI for 10 min. After a washing procedure, sections
were mounted in DAKO fluorescent mounting medium
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(Dako Deutschland GmbH, Hamburg, Germany) and
analyzed with an Axioskop2 MOT Plus Apotome micro-
scope (Carl Zeiss). Quantitative morphometric analyses
were performed by counting the number of rows of
photoreceptor nuclei along the nasal/temporal axis.
Flow cytometry
Mouse retinas were dissected 4 days after light exposure
and dissociated using the Neuronal Tissue Dissociation Kit-
Postnatal Neurons (MACS, Miltenyi, Bergisch Gladbach,
Germany). To identify microglia cells and macrophages,
the single-cell suspension was stained with anti-mouse/hu-
man CD11b-APC antibody (MACS, Miltenyi, Bergisch
Gladbach, Germany) at a dilution of 1:10 for 15 min in the
dark at 4 °C. After a washing step, cells were fixed with
FluoroFix Buffer (Biolegend, San Diego, CA, USA) in the
dark for 30 min at room temperature. Afterwards, the cells
were washed and resuspended in PBS solution (pH 7.2,
0.5 % containing bovine serum albumin (BSA), and
2 mM EDTA) until flow cytometric analyses with a
fluorescence-activated cell sorting (FACS) Canto II (Becton
Dickinson, Heidelberg, Germany). The number of CD11b+
cells was determined using FlowJo software (Treestar,
Ashland, USA).
Statistical analysis
The differences between control mice and animals after
light exposure that either received sham injections or
XBD173 injections were analyzed using a one-way ANOVA
and Dunnett’s multiple comparison test. p < 0.05 was con-
sidered statistically significant.
Results
The TSPO ligand XBD173 prevents microglia reactivity
and gliosis in murine retinas exposed to acute white light
We have previously identified that Tspo mRNA and pro-
tein are highly induced in genetic models of retinal degen-
eration and that its specific ligand XBD173 has potent
anti-inflammatory activity on microglia in vitro [16]. Based
on these data, we hypothesized that XBD173 could also
modulate microglial responses in the damaged retina in
vivo. We have chosen acute light-induced degeneration as
it is a fast and reproducible mouse model that mimics sev-
eral features of human retinal degenerative diseases in-
cluding innate immune activation and selective cell death
of photoreceptor cells [33].
Dark-adapted BALB/cJ mice were exposed to white light
with an intensity of 15,000 lux for 1 h. The animals re-
ceived daily intraperitoneal injections of 10 mg/kg XBD173
or vehicle, starting 1 day before the light exposure for five
consecutive days (Fig. 1a). Four days after light exposure,
the effects of XBD173 treatment on microgliosis were an-
alyzed by staining of retinal sections and flat mounts. In
healthy controls, immunolabeling of retinal sections with
the marker IBA1 showed ramified microglia exclusively in
the plexiform layers and inner retina (Fig. 1b). Light ex-
posure and vehicle administration induced strong micro-
glia reactivity resulting in the migration and appearance of
amoeboid-shaped microglia in the degenerating photo-
receptor layer and the subretinal area (Fig. 1c). This severe
thinning of the outer retina and accumulation of microglia
in and around the outer nuclear layer was not detectable
in mice treated with XBD173 (Fig. 1d). We next analyzed
changes in the microglial network in retinal flat mounts
stained with Iba1. In contrast to controls, where microglial
cells are highly ramified in the outer plexiform layer
(OPL) (Fig. 1e), light-exposed retinas showed clear signs
of microglia reactivity in the OPL (Fig. 1f), which was
reverted in conditions of XBD173 therapy (Fig. 1g). Fur-
thermore, the appearance of many amoeboid-shaped
microglia in the subretinal area triggered by light exposure
was strongly reduced in the XBD173 treatment group
(Fig. 1h–j). This finding that XBD173 very likely prevented
migration of many microglia from the inner to the outer
retina was corroborated by a quantitative analysis count-
ing the number of microglial cells in the outer nuclear
layer (ONL) and subretinal area (Fig. 1k, l). We then de-
termined the number of CD11b-positive cells in the retina
using flow cytometry. These data also showed that
XBD173 administration strongly reduced the percentage
of CD11b-positive cells in the light-exposed retina com-
pared to vehicle controls (Fig. 1m–p).
We then wanted to better characterize the reactive glio-
sis and its relation to the expression of TSPO itself. Expos-
ure to light in the vehicle control triggered strong
expression of TSPO that was mainly confined to outer ret-
inal microglia and some astrocytes in the ganglion cell
layer (Fig. 2a, b). This cellular expression pattern is in
agreement with previous immunohistochemical data from
genetic mouse models of retinal degeneration [16, 37] and
highlights the induced expression of TSPO in microglia
upon activation. Administration of XBD173 strongly di-
minished TSPO expression (Fig. 2c), indicating a much less
reactive microgliosis and confirming our stainings with
Iba1 (Fig. 1). Interestingly, we also identified specific ex-
pression of TSPO in the retinal pigment epithelium (RPE)
network that was visualized by co-staining with phalloidin
(Fig. 2d). However, this RPE-specific expression pattern of
TSPO was not obviously influenced by light exposure or
XBD173 therapy (Fig. 2e, f), indicating a constitutive role of
TSPO in the RPE that is unrelated to gliosis. We then ana-
lyzed the expression of glutamine synthetase (GS), a consti-
tutively expressed Müller cell protein and glial fibrillary
acid protein (GFAP), a marker für Müller cell and astrocyte
reactivity. GS staining was not significantly changed by light
exposure and XBD173 treatment (Fig. 2g–i, m), whereas
XBD173 significantly reduced the light-dependent induc-
tion of GFAP expression (Fig. 2j–l, n). These findings
Scholz et al. Journal of Neuroinflammation  (2015) 12:201 Page 4 of 12
Fig. 1 XBD173 treatment of light-exposed mice prevents microglia reactivity. a Light exposure regimen and mode of XBD173 administration.
Representative photomicrographs show retinal sections (b–d) and flat mounts (e–j) stained with IBA1 (green) and DAPI (blue). In control retinas,
microglial cells were located in the OPL, IPL, and GCL (b, e, h). Light-exposed retinas injected with vehicle control showed a massive thinning of
the ONL and many amoeboid-shaped, reactive microglia in the ONL and the subretinal space (c, f, i). Compared to vehicle controls, the ONL of
XBD173-treated retinas appeared markedly preserved and less amoeboid microglia were detectable in the ONL and the subretinal space (d, g, j).
The total number of Iba1-positive microglial cells in the ONL (k) and the subretinal area (l) after light damage was significantly reduced in the
XBD173 therapy group. Data show mean ± SEM (control n = 3, light exposure and vehicle treatment n = 6, light exposure and XBD173 treatment
n = 12 sections). The percentage of CD11b-positive cells in the retina as determined by flow cytometry was strongly reduced by XBD173
treatment in representative FACS plots (m–o) and quantitative analyses of n = 3–4 retinas (p). ONL outer nuclear layer, OPL outer plexiform
layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar 50 μm
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Fig. 2 XBD173 treatment of light-exposed mice down-regulates TSPO in microglia and prevents gliosis. Representative photomicrographs of retinal
sections and flat mounts from mice 4 days after light exposure. Control retinas show weak TSPO labeling (a), and strong up-regulation of TSPO
expression confined to microglia was present upon light exposure and vehicle treatment (b). XBD173-treated mice displayed only constitutive
expression of TSPO in the RPE, but no strong signal in the retina was found (c). Number of analyzed photomicrographs: control n = 5 sections
from two individual mice, light exposure and vehicle treatment n = 7 sections from five individual mice, light exposure and XBD173 treatment
n = 11 sections from five individual mice. The expression of TSPO in the RPE was relatively unaffected in the different conditions as shown in
flat mount images stained with anti-TSPO antibody and phalloidin (d–f). Glutamine synthetase (GS), a constitutive Müller cell protein, and glial
fibrillary acidic protein (GFAP) as markers for gliosis were analyzed (g–n). GS expression did not differ in the various treatment groups (g–i, m)
whereas GFAP expression was changed significantly (j–l, n). Data show mean ± SEM (control n = 5 sections from five individual mice, light exposure and
vehicle treatment n = 5 sections from three individual mice, light exposure and XBD173 treatment n = 5 sections from four individual mice). **p < 0.01.
ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. Scale bar 50 μm
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indicate that gliosis triggered by light damage can be pre-
vented by targeting TSPO.
XBD173 reduces pro-inflammatory gene expression in
retinal degeneration
In addition to these cellular analyses of retinal microglia,
we investigated whether mRNA levels of pro-inflammatory
transcripts were influenced by XBD173 administration in
vivo. CD68, activated microglia/macrophage whey acidic
protein (AMWAP), and TSPO itself are molecules that
are connected with microglia proliferation and reactiv-
ity [16, 38, 39]. Four days after light exposure, all three
genes were induced in the retina, with especially high
levels of Amwap (Fig. 3a–c). In light-exposed mice treated
with XBD173, the expression of Cd68 (Fig. 3a, p = 0.0342),
Amwap (Fig. 3b, p = 0.0182), and Tspo (Fig. 3c, p = 0.0338)
were significantly suppressed. Furthermore, transcripts
that reflect the activation of key microglial pathways in-
cluding chemotaxis, pro-inflammatory cytokines, and rad-
ical production were analyzed. mRNA levels of the
chemotactic molecule Ccl2 and the cytokine Il6 were
strongly up-regulated in the retinas of sham-injected
light-exposed mice, and XBD173 administration dimin-
ished their expression (Fig. 3d, e). Notably, the expression
of iNos was not significantly altered by light exposure or
XBD173 treatment (Fig. 3f) potentially indicating different
time kinetics of chemokine/cytokine levels and oxygen
radical responses. These data suggest that XBD173 has
potent microglia-related immuno-modulatory effects in
vivo in the mouse retina.
XBD173 treatment prevents light-induced retinal
degeneration
We next asked whether targeting TSPO with XBD173 also
improves the outcome of disease progression. We first per-
formed in vivo optical coherence tomography (OCT) to
detect the retinal damage after light exposure and under
conditions of XBD173 treatment. The OCT images
showed clear changes especially in ONL reflectance in the
retinas of sham-treated light-exposed mice, indicating a se-
vere degeneration of the photoreceptor layer (Fig. 4a, b). In
contrast, XBD173-treated animals displayed nearly normal
retinal layers similar to that of healthy controls (Fig. 4c).
Volume scans revealed a significant thinning of the retinal
tissue, especially in the central area around the optic nerve
head after light exposure, which was much less pro-
nounced in the XBD173-treated groups (Fig. 4d–f). Quan-
tification of the retinal thickness in all analyzed animals
demonstrates a significant reduction in the 3- and 6-mm
central areas, respectively, after light exposure (p < 0.0001),
Fig. 3 XBD173 treatment dampens microglia-related pro-inflammatory marker expression after light exposure. To determine the mRNA expression
of inflammation-associated genes in the retina, qRT-PCR analysis was performed 4 days after light exposure. a–c The microglia markers Cd68 and
Amwap were up-regulated after light exposure, and TSPO levels were also increased. In contrast, the retinas from XBD173-treated mice expressed
significantly less Cd68, Amwap, and Tspo transcripts after light exposure. d, e XBD173 treatment reduced the expression of Ccl2 and Il6 that were
elevated by light exposure. f iNOS expression was not altered. Data show mean ± SEM out of three independent experiments (control n = 4–8,
light exposure plus vehicle treatment n = 8–15, light exposure plus XBD173 treatment n = 8–15 per group, measured in duplicates) with *p < 0.05;
**p < 0.01; ***p < 0.001
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that could be rescued by administration of XBD173
(p < 0.0001) (Fig. 4g, h).
To confirm these findings on the histological level,
panorama images of retinal sections proceeding through
the optic nerve head obtained 4 days after light exposure
were stained with DAPI (Fig. 5a–c). The photoreceptor
layer showed a clear thinning in sham-injected mice ex-
posed to light, which was not evident in mice after
XBD173 administration (Fig. 5a–c). In accordance with
these data, the number of terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL)-positive cells as
indicators of cell death was also increased with light and
strongly reduced by XBD173 injection (Fig. 5d, e). Further
quantitative morphometric analyses along the nasal/tem-
poral axis revealed that light exposure especially reduced
the central retinal thickness and that this decline was sig-
nificantly less in the XBD173-treated group of mice
(Fig. 5g). Moreover, molecular analyses using quantitative
real-time PCR (qRT-PCR) of total retinal RNA detected a
clear counter-regulatory effect of XBD173 on caspase 8
mRNA levels (Fig. 5h, p = 0.0007). These data together
clearly point towards a strong neuroprotective effect of
XBD173 in conditions of light damage.
XBD173 prevents focal light-induced retinal damage
We were finally interested to validate our findings in an
independent model using focal light-induced retinal dam-
age. Cx3cr1GFP/+ reporter mouse eyes, which facilitate
label-free microglia visualization, were exposed to 50,000
lux cold light delivered by an otoscope for 10 min in the
Fig. 4 XBD173 preserves retinal thickness in light-exposed mice. SD-OCT was performed 4 days after light exposure to analyze changes in retinal
structures. a–c Light-exposed mice show an altered reflectance in the ONL, which was not present in XBD173-treated mice. d–f Representative
heat maps show the average retinal thickness of control and light-exposed mice after vehicle or XBD173 treatment, respectively. Light-exposed
mice show a significant thinning of the retina, in the central (g) and more peripheral area (h), which was preserved by XBD173 treatment. g, h
One data point represents the average thickness of the central retina, calculated from four different areas around the optic nerve head in circle
diameters of 3 mm (g) and 6 mm (h), respectively. Data show mean ± SEM out of two independent experiments (control n = 6, light exposure
plus vehicle treatment n = 10, light exposure plus XBD173 treatment n = 10/group) with ***p < 0.001
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same experimental design as described above for complete
light exposure (Fig. 6a). Fundus imaging showed a clear
focal light-induced retinal damage with a central area of
atrophy (Fig. 6b). Confocal imaging of GFP-positive ONL
microglia within the retinal lesion area of sham-treated
mice clearly indicated a reactive phenotype compared
to controls and XBD173-injected animals, respectively
(Fig. 6c–e). As short cellular processes and enlargement of
soma are characteristic for microglial activation, we quanti-
fied this morphological change using a grid system by
counting the points of all cells that crossed the grid as de-
scribed previously [40]. This analysis showed a significant
reduction of grid cross points in focal light-exposed retinas,
and this was fully reverted in the XBD173-treated group of
animals (Fig. 6f).
In the last set of experiments, we determined the num-
ber of cone photoreceptors in the focal light damage
model using confocal microscopy of retinal flat mounts
that were stained with anti-cone arrestin antibodies. The
areas of focal light damage showed a much weaker arrestin
staining compared to controls and compared to the retinas
of XBD173-treated animals, respectively (Fig. 6g–i). The
quantitative analysis of 6–8 independent retinas revealed a
more than 8-fold reduction in the number of cone
Fig. 5 XBD173 protects the light-exposed retina from cell death. a–c Representative panorama sections of the retina were stained with DAPI to
further characterize structural changes. Light exposure caused severe degeneration particularly of the ONL. XBD173 administration reduced
degeneration, represented by a clearly thicker photoreceptor layer, scale bar 200 μM. d–f Representative photomicrographs of TUNEL-stained
retinal sections show the amount of apoptotic cells 4 days after light exposure. Light exposure caused a strong increase of apoptotic cells, especially in
the ONL. Only very few TUNEL-positive cells were visible after XBD173 administration. Scale bar 50 μm (g). For quantification of retinal thickness, anterior
and posterior areas were divided into ten sections with the optic nerve as reference and rows of photoreceptor nuclei were counted. Data
show mean ± SEM (control n = 4, light exposure plus vehicle treatment n = 8, light exposure plus XBD173 treatment n = 10/group) with *p < 0.05;
**p < 0.01; ***p < 0.001 light exposed + vehicle versus control (red color) and light exposed + XBD173 versus light exposed + vehicle (blue color).
h mRNA analyses revealed a significantly lower expression of caspase 8 in light-exposed XBD173-treated mice compared to controls and vehicle-injected
retinas. Data show mean ± SEM out of two independent experiments (control n= 4, light exposure plus vehicle treatment n= 8, light exposure plus
XBD173 treatment n= 8/group, measured in triplicates) with **p< 0.01; ***p< 0.001
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photoreceptors upon light damage and a 4.8-fold increase
in the XBD173 therapy group, indicating a prominent ef-
fect on photoreceptor survival (Fig. 6j).
Discussion
Due to its high expression in activated glia, TSPO is a
marker for brain gliosis and TSPO ligands are commonly
used for in vivo imaging in humans and mice [41, 42]. We
have previously identified high TSPO levels in retinal
microglia of murine models of inherited retinal degener-
ation [16, 37]. In the present study, we now show that
TSPO is also strongly induced in retinal microglia after
light exposure and that the TSPO ligand XBD173 has po-
tent microglia-modulatory and neuroprotective functions
in the retina in vivo. To our knowledge, this is the first re-
port of TSPO-directed pharmacological targeting of the
diseased retina.
To mimic exposure to bright daylight, which is a well-
known environmental risk factor for retinal degenerations,
we exposed the mice to 15,000 lux UV-free white light for
1 h in the first set of experiments and to 50,000 lux focal
cold white light for 10 min in the validation studies. White
light has an emission spectrum relatively similar to that of
daylight, and it is less artificial than the light of a particular
wavelength [43, 44]. Furthermore, white light contains a
significant fraction of short-wavelength blue light (403 nm)
which is thought to have a higher damaging potential
than the light of longer wavelength including green
light (490–580 nm), which was used in some studies to
mimic retinal degeneration [45]. The higher damaging
potential of blue light is due to a process called photo-
reversal, the regeneration of rhodopsin from bleaching
intermediates that results in a higher number of photon
absorption in a certain time span [46].
Very early microglial activation was observed already
1 day after light challenge in both models (data not shown),
indicating that microglia sense subtle disturbances in the
light-damaged retina before overt cell death occurs. TSPO
Fig. 6 XBD173 treatment prevents microglia reactivity and rescues cone photoreceptors in focal light-induced damage. a Light exposure regimen
and mode of XBD173 administration. b Representative fundus image showing the focal light lesion 4 days after Cx3cr1GFP/+ mice were exposed
to 50,000 lux for 10 min. c–e Representative confocal images of GFP-positive retinal microglia in flat mounts from control mice (c) and lesion
areas of light-exposed mice (d, e). The average size of microglial cells was assessed using the grid cross point system (f). Data show mean ± SEM
(n= 40–180 cells per group) with ***p< 0.001. g–i Retinal flat mounts were processed for cone arrestin staining and examined by confocal microscopy.
Representative confocal images of cone arrestin-positive cells in flat mounts from control mice (g) and lesion areas of light-exposed mice (h, i). j Average
density of cone photoreceptor cells. Data show mean ± SEM (n= 6–8 retinas per group) with *p< 0.05; ***p< 0.001. Scale bar 50 μm
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expression was present in these reactive microglia, and our
analyses towards the phenotype and behavior of microglia
together with previous in vitro data [16] suggest that
XBD173 exerts its neuroprotective function at least par-
tially via modulation of microglia. Likewise, another spe-
cific TSPO ligand, etifoxine, also potently diminished
inflammatory pathology and thereby attenuated the clinical
score of experimental autoimmune encephalomyelitis, an
experimental mouse model for multiple sclerosis [25]. The
tight correlation of microglia reactivity with TSPO expres-
sion was also identified in the genetic mouse model of my-
osin VII deficiency that mimics both features of retinal
dystrophies and glaucoma [47]. Therefore, TSPO induction
in retinal microglia may be an early and reliable marker for
changes in the microglia phenotype in different types of
retinal degenerative diseases [37].
Our mRNA expression data of XBD173-treated retinas
showed not only decreased transcript levels of Cd68,
Amwap, and Tspo but also reduced Ccl2 and Il6 expres-
sion. The CCL2/CCR2 axis is crucial in subretinal macro-
phage and microglia accumulation in retinal degeneration
models and human AMD, and these findings implicate that
CCL2/CCR2 inhibition may be a novel tool to limit inflam-
mation and neurodegeneration in the retina [48, 49]. Simi-
larly, human reactive microglia express IL6, which in turn
prevents retinal regeneration and promotes subretinal im-
mune cell survival [50, 51]. Thus, the XBD173/TSPO axis
seems to target two key pathways of chronic microglia re-
activity in the retina.
As we have shown previously in microglial cell cultures
[16], one potential mechanism of the anti-inflammatory
effects of XBD173 could be the local synthesis of pregnen-
olone, as has been also demonstrated for brain astrocytes
[52]. Pregnenolone can be further metabolized to proges-
terone and allopregnanolone that are both potent neuro-
protective and anti-inflammatory molecules [53–55].
When orally applied to rd1 mice with inherited retinal de-
generation, progesterone potently reduced oxidative stress
levels, diminished gliosis, and provided a temporal im-
provement in photoreceptor function [56].
We have demonstrated constitutive mitochondrial TSPO
expression in the RPE that was unaffected by light exposure
or XBD173 therapy. Therefore, TSPO in RPE mitochondria
could potentially fulfill a housekeeping function. Of note,
increased damage of mitochondrial DNA specifically in the
RPE has been recently implicated as a risk factor for AMD
and mutations of electron transport chain components
could potentially limit energy production [57]. Thus, in
addition to its anti-inflammatory effects on microglia,
TSPO may sustain mitochondrial homeostasis and integrity
by regulating the oxygen consumption rate. However, this
function and the previously identified physiological roles of
TSPO remain to be characterized with novel cell-type spe-
cific knockout mouse models [58, 59].
Conclusions
We have shown that modulation of microglia with the syn-
thetic TSPO ligand XBD173 preserved the retinal structure
by counter-regulation of microglial pro-inflammatory re-
sponses during light exposure. Our data suggest that tar-
geting TSPO in the retina may be a novel promising
approach for anti-inflammatory and neuroprotective ther-
apies in retinal degenerative disorders.
Competing interests
All authors declare no competing financial interests.
Authors’ contributions
RS designed the research, performed the research, and analyzed the data.
AC, MB, KR, and MC performed the research and analyzed the data. HX and
CG designed the research and wrote the paper. TL designed the research,
analyzed the data, obtained the funding, and wrote the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the DFG (LA1203/6-2, LA1203/9-1, LA1203/10-1,
and FOR2240), the Velux Foundation, the Hans und Marlies Stock-
Foundation, the Pro Retina Foundation, the Bayer Graduate Program in
Pharmacology, and Fight for Sight (1425/1426). We thank the members of
the Brachvogel Laboratory, Institute of Biochemistry, University of Cologne,
for their help with the FACS analyses.
Author details
1Department of Ophthalmology, Laboratory for Experimental Immunology of
the Eye, University of Cologne, 50931 Cologne, Germany. 2Centre for
Experimental Medicine, School of Medicine, Dentistry and Biomedical
Sciences, Queen’s University Belfast, Belfast BT12 6BA, UK. 3Department of
Ophthalmology, Lab for Retinal Cell Biology, University of Zürich, 8057
Zürich, Switzerland.
Received: 23 September 2015 Accepted: 26 October 2015
References
1. Hume DA, Perry VH, Gordon S. Immunohistochemical localization of a
macrophage-specific antigen in developing mouse retina: phagocytosis of
dying neurons and differentiation of microglial cells to form a regular array
in the plexiform layers. J Cell Biol. 1983;97:253–7.
2. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia.
Physiol Rev. 2011;91:461–553.
3. Damani MR, Zhao L, Fontainhas AM, Amaral J, Fariss RN, Wong WT. Age-related
alterations in the dynamic behavior of microglia. Aging Cell. 2011;10:263–76.
4. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly
dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–8.
5. Aloisi F. Immune function of microglia. Glia. 2001;36:165–79.
6. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis
pigmentosa, late-onset retinal degeneration, and age-related macular
degeneration. Exp Eye Res. 2003;76:463–71.
7. Langmann T. Microglia activation in retinal degeneration. J Leukoc Biol.
2007;81:1345–51.
8. Karlstetter M, Langmann T. Microglia in the aging retina. Adv Exp Med Biol.
2014;801:207–12.
9. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog
Retin Eye Res. 2009;28:348–68.
10. Zhao L, Zabel MK, Wang X, Ma W, Shah P, Fariss RN, et al. Microglial
phagocytosis of living photoreceptors contributes to inherited retinal
degeneration. EMBO Mol Med. 2015;7(9):1179–97.
11. Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from
aging mice exhibit an altered inflammatory profile. Glia. 2007;55:412–24.
12. Roque RS, Rosales AA, Jingjing L, Agarwal N, Al-Ubaidi MR. Retina-derived
microglial cells induce photoreceptor cell death in vitro. Brain Res.
1999;836:110–9.
13. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al.
Blockade of microglial activation is neuroprotective in the 1-methyl-4-
Scholz et al. Journal of Neuroinflammation  (2015) 12:201 Page 11 of 12
phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
J Neurosci. 2002;22:1763–71.
14. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative
diseases. Immunology. 2010;129:154–69.
15. Chen M, Xu H. Parainflammation, chronic inflammation, and age-related
macular degeneration. J Leukoc Biol. 2015.
16. Karlstetter M, Nothdurfter C, Aslanidis A, Moeller K, Horn F, Scholz R, et al.
Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal
microglia and modulates microglial inflammation and phagocytosis.
J Neuroinflammation. 2014;11:3.
17. Wang M, Wang X, Zhao L, Ma W, Rodriguez IR, Fariss RN, et al. Macroglia-
microglia interactions via TSPO signaling regulates microglial activation in
the mouse retina. J Neurosci. 2014;34:3793–806.
18. Papadopoulos V, Liu J, Culty M. Is there a mitochondrial signaling complex
facilitating cholesterol import? Mol Cell Endocrinol. 2007;265–266:59–64.
19. Kuhlmann AC, Guilarte TR. Cellular and subcellular localization of peripheral
benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem.
2000;74:1694–704.
20. Maeda J, Higuchi M, Inaji M, Ji B, Haneda E, Okauchi T, et al. Phase-dependent
roles of reactive microglia and astrocytes in nervous system injury as
delineated by imaging of peripheral benzodiazepine receptor. Brain Res.
2007;1157:100–11.
21. Veiga S, Azcoitia I, Garcia-Segura LM. Extragonadal synthesis of estradiol is
protective against kainic acid excitotoxic damage to the hippocampus.
Neuroreport. 2005;16:1599–603.
22. Girard C, Liu S, Adams D, Lacroix C, Sineus M, Boucher C, et al. Axonal
regeneration and neuroinflammation: roles for the translocator protein
18 kDa. J Neuroendocrinol. 2012;24:71–81.
23. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor
of brain injury and repair. Pharmacol Ther. 2008;118:1–17.
24. Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee JW, Melcangi RC,
et al. Ligand for translocator protein reverses pathology in a mouse model
of Alzheimer’s disease. J Neurosci. 2013;33:8891–7.
25. Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE, Deng W. A
TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol
Med. 2013;5:891–903.
26. Wei XH, Wei X, Chen FY, Zang Y, Xin WJ, Pang RP, et al. The upregulation of
translocator protein (18 kDa) promotes recovery from neuropathic pain in
rats. J Neurosci. 2013;33:1540–51.
27. Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, et al.
Translocator protein (18 kD) as target for anxiolytics without
benzodiazepine-like side effects. Science. 2009;325:490–3.
28. Nothdurfter C, Rammes G, Baghai TC, Schule C, Schumacher M,
Papadopoulos V, et al. Translocator protein (18 kDa) as a target for novel
anxiolytics with a favourable side-effect profile. J Neuroendocrinol.
2012;24:82–92.
29. Nothdurfter C, Baghai TC, Schule C, Rupprecht R. Translocator protein
(18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders.
Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 2:S107–12.
30. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al.
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological
and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971–88.
31. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular
degeneration. The beaver dam eye study. Arch Ophthalmol. 1993;111:514–8.
32. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial
late-onset disease: from genetic susceptibility to disease mechanisms for age-
related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10:19–43.
33. Grimm C, Reme CE. Light damage as a model of retinal degeneration.
Methods Mol Biol. 2013;935:87–97.
34. Marc RE, Jones BW, Watt CB, Vazquez-Chona F, Vaughan DK, Organisciak DT.
Extreme retinal remodeling triggered by light damage: implications for age
related macular degeneration. Mol Vis. 2008;14:782–806.
35. Narimatsu T, Ozawa Y, Miyake S, Kubota S, Hirasawa M, Nagai N, et al.
Disruption of cell-cell junctions and induction of pathological cytokines in
the retinal pigment epithelium of light-exposed mice. Invest Ophthalmol Vis
Sci. 2013;54:4555–62.
36. Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related
macular degeneration. Mol Aspects Med. 2012;33:487–509.
37. Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal
microglia: just bystander or target for therapy? Prog Retin Eye Res.
2015;45:30–57.
38. Karlstetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, et al.
The novel activated microglia/macrophage WAP domain protein, AMWAP,
acts as a counter-regulator of proinflammatory response. J Immunol.
2010;185:3379–90.
39. Aslanidis A, Karlstetter M, Scholz R, Fauser S, Neumann H, Fried C, et al.
Activated microglia/macrophage whey acidic protein (AMWAP) inhibits
NFkappaB signaling and induces a neuroprotective phenotype in microglia.
J Neuroinflammation. 2015;12:77.
40. Chen M, Zhao J, Luo C, Pandi SP, Penalva RG, Fitzgerald DC, et al. Para-
inflammation-mediated retinal recruitment of bone marrow-derived
myeloid cells following whole-body irradiation is CCL2 dependent. Glia.
2012;60:833–42.
41. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of
neuroinflammation: a comprehensive review of [11C]PK11195 challengers.
Eur J Nucl Med Mol Imaging. 2008;35:2304–19.
42. Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/
macrophages in the brain. Glia. 2013;61:10–23.
43. Wenzel A, Grimm C, Samardzija M, Reme CE. Molecular mechanisms of
light-induced photoreceptor apoptosis and neuroprotection for retinal
degeneration. Prog Retin Eye Res. 2005;24:275–306.
44. Youssef PN, Sheibani N, Albert DM. Retinal light toxicity. Eye (Lond). 2011;25:1–14.
45. Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MO. Neuroprotection of
photoreceptors by minocycline in light-induced retinal degeneration. Invest
Ophthalmol Vis Sci. 2004;45:2753–9.
46. Grimm C, Wenzel A, Williams T, Rol P, Hafezi F, Reme C. Rhodopsin-
mediated blue-light damage to the rat retina: effect of photoreversal of
bleaching. Invest Ophthalmol Vis Sci. 2001;42:497–505.
47. Schubert T, Gleiser C, Heiduschka P, Franz C, Nagel-Wolfrum K, Sahaboglu A, et al.
Deletion of myosin VI causes slow retinal optic neuropathy and age-related
macular degeneration (AMD)-relevant retinal phenotype. Cell Mol Life Sci.
2015;72(20):3953–69.
48. Raoul W, Auvynet C, Camelo S, Guillonneau X, Feumi C, Combadiere C,
et al. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible
involvement in age-related macular degeneration. J Neuroinflammation.
2010;7:87.
49. Sennlaub F, Auvynet C, Calippe B, Lavalette S, Poupel L, Hu SJ, et al.
CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease
and mediate photoreceptor degeneration in experimental subretinal
inflammation in Cx3cr1 deficient mice. EMBO Mol Med. 2013;5:1775–93.
50. Balasubramaniam B, Carter DA, Mayer EJ, Dick AD. Microglia derived IL-6
suppresses neurosphere generation from adult human retinal cell
suspensions. Exp Eye Res. 2009;89:757–66.
51. Levy O, Calippe B, Lavalette S, Hu SJ, Raoul W, Dominguez E, et al.
Apolipoprotein E promotes subretinal mononuclear phagocyte survival and
chronic inflammation in age-related macular degeneration. EMBO Mol Med.
2015;7:211–26.
52. Cascio C, Brown RC, Liu Y, Han Z, Hales DB, Papadopoulos V. Pathways of
dehydroepiandrosterone formation in rat brain glia. J Steroid Biochem Mol
Biol. 2000;75:177–86.
53. Yao XL, Liu J, Lee E, Ling GS, McCabe JT. Progesterone differentially
regulates pro- and anti-apoptotic gene expression in cerebral cortex
following traumatic brain injury in rats. J Neurotrauma. 2005;22:656–68.
54. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids
progesterone and allopregnanolone reduce cell death, gliosis, and
functional deficits after traumatic brain injury in rats. J Neurotrauma.
2005;22:106–18.
55. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone
decrease cell death and cognitive deficits after a contusion of the rat pre-frontal
cortex. Neuroscience. 2004;123:349–59.
56. Sanchez-Vallejo V, Benlloch-Navarro S, Lopez-Pedrajas R, Romero FJ, Miranda
M. Neuroprotective actions of progesterone in an in vivo model of retinitis
pigmentosa. Pharmacol Res. 2015;99:276–88.
57. Terluk MR, Kapphahn RJ, Soukup LM, Gong H, Gallardo C, Montezuma SR,
et al. Investigating mitochondria as a target for treating age-related macular
degeneration. J Neurosci. 2015;35:7304–11.
58. Selvaraj V, Stocco DM. The changing landscape in translocator protein
(TSPO) function. Trends Endocrinol Metab. 2015;26:341–8.
59. Gut P, Zweckstetter M, Banati RB. Lost in translocation: the functions of the
18-kD translocator protein. Trends Endocrinol Metab. 2015;26:349–56.
Scholz et al. Journal of Neuroinflammation  (2015) 12:201 Page 12 of 12
